$GILD

Mercier Johanna sold $3.9M of GILD

Mercier Johanna (Chief Comm & Corp Aff Officer) sold 28,000 shares of GILEAD SCIENCES, INC. (GILD) at an average of $137.64 ($137.36–$138.04, $3.85M total) across 2 trades on 2026-08-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Mercier Johanna
Published Aug 18, 2026, 10:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 11:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GILD
Neutral
high confidence
Mentioned
$GILD
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GILDNeutralLow
01

Why it matters

The disclosed fact is the insider’s sale details (shares, price range, total value) and that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may treat this as low-signal insider activity because it is explicitly under a 10b5-1 plan, with limited incremental information for valuation.

03

What to watch

The article provides sale size and price range but not context like total compensation, prior sale cadence, or whether other insiders also sold around the same window.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-18 after trades on 2026-08-17

Background

The article is a SEC Form 4 insider transaction disclosure for Gilead Sciences, filed on 2026-08-18.

Company-level read

Ticker impact

$GILDNeutralHigh confidence
Context

Gilead insider Mercier Johanna sold about 28,000 shares in open-market trades at roughly $137.37 to $138.04 on 2026-08-17.

Expected impact

Low likelihood of a sustained price move solely from this filing; any reaction is likely muted.

Evidence & confidence

The filing specifies an open-market sale and a pre-arranged Rule 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.

Market effects

No clear sector read-through; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with internal caution, so traders may still watch for follow-on disclosures.

Key entities

  • Gilead Sciences, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Mercier Johanna

    Chief Comm and Corp Aff Officer who sold shares.

  • Rule 10b5-1 plan

    Pre-arranged plan cited as Yes in the filing.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GILDMed

5 Breast Cancer Advances in 2026—And The Questions They Leave Unanswered

The FDA approved several breast cancer treatments in 2026, including Daiichi Sankyo's fam-trastuzumab deruxtecan for early-stage HER2-positive breast cancer, datopotamab deruxtecan for triple-negative breast cancer, Gilead Sciences' sacituzumab govitecan for first-line TNBC, Pfizer's palbociclib for maintenance therapy, and AstraZeneca's camizestrant for HR-positive, HER2-negative advanced breast cancer.

$GILDHighAI 9/10

Gilead and Vir forge $1.9bn pact to develop next-gen T-cell engagers

Gilead Sciences and Vir Biotechnology agreed to collaborate on developing T-cell engager therapies for solid tumors. Gilead will pay $90m upfront, including $65m in cash and $25m in equity, with up to $1.74bn in potential milestones. Gilead will lead development and commercialization, using Vir's PRO-XTEN technology and AI platform. This follows their 2021 hepatitis B drug collaboration and Vir's recent deal with Astellas.

$VIRHighAI 9/10

Vir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal

Vir Biotechnology and Gilead Sciences agreed to collaborate on cancer therapies for solid tumors, with a deal potentially worth up to $1.88 billion. Vir will receive $90 million upfront and could earn additional milestone payments and royalties. The partnership focuses on developing three drug candidates using Vir's technologies. Vir shares rose over 10% in premarket trading.

$VIRHighAI 8/10

Vir Biotechnology partners with Gilead on cancer therapies

Vir Biotechnology (VIR) and Gilead Sciences (GILD) announced a collaboration to develop cancer therapies. VIR will receive $90M upfront, with potential milestones up to $1.74B. VIR will handle discovery, while GILD will develop and commercialize the therapies. The deal focuses on T-cell engagers targeting solid tumors.